Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses how his company has adjusted to pandemic-related disruption on the fundraising trail without missing a beat. He walks us through the remote-fundraising strategy that landed Bolt’s recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and political tumult.